Acadia sells Rare Pediatric Disease PRV for $150M, one third to partner Neuren

ACADIA PHARMACEUTICALS INC

Closed sale of PRV for $150M on Dec 11, 2024, after HSR waiting period expired.
PRV awarded March 2023 from FDA approval of DAYBUE (trofinetide) for Rett syndrome.
One third of net proceeds payable to Neuren under July 2023 joint venture agreement.
Material terms of PRV Transfer Agreement previously disclosed in Q3 2024 10-Q.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.